Thus, a clinical study in a larger cohort will need to elucidate if this impairs the imaging and dosimetry outcome of 89Zr-PSMA in prostate cancer (e.g., in bone metastases or bone marrow). Here, FOLH1 is linked to prostate carcinoma.